The Royal Palace in Oslo has confirmed that Crown Princess Mette-Marit of Norway has undergone a successful lung transplant, a procedure necessitated by the progressive pulmonary fibrosis she has battled for years. The surgery was performed at the Rigshospitalet in Copenhagen, but the palace has extended particular gratitude to the medical teams at the University Hospital of Southampton and the Royal Brompton and Harefield hospitals in the United Kingdom for their pre-operative assessments and ongoing clinical collaboration.
In a statement released this morning, the palace said the crown princess is recovering well in intensive care and that the prognosis is cautiously optimistic. Pulmonary fibrosis, a condition that causes progressive scarring of lung tissue, had forced Mette-Marit to reduce her public duties significantly since 2018. The transplant, which replaces damaged lungs with healthy donor organs, offers the possibility of substantially improved respiratory function and quality of life.
The UK connection is notable. The National Health Service’s specialist transplant centres have some of the highest success rates in Europe for complex lung procedures, and their involvement underscores the international cooperation often required in such high-stakes surgeries. The palace highlighted the tireless work of the British clinicians in preparing the crown princess for the operation and in her post-operative care regimen.
Crown Princess Mette-Marit, 51, is married to Crown Prince Haakon, heir to the Norwegian throne. She has been a prominent advocate for public health issues, particularly concerning rare diseases and mental health. Her own medical journey has been followed closely in Norway, where the royal family is deeply respected. The announcement was met with an outpouring of support from the Norwegian public and from other European royal households.
The operation itself lasted more than eight hours and involved a multidisciplinary team of thoracic surgeons, anaesthetists, and perfusionists. The hospital has not released details about the donor, in keeping with standard protocols to protect anonymity. However, the palace acknowledged the profound generosity of the donor and their family, stating that their gift of life has given the crown princess a second chance.
Medical experts note that lung transplants carry significant risks, including rejection and infection, but that modern immunosuppressive therapies have markedly improved long-term outcomes. The five-year survival rate for lung transplant recipients is now approximately 60 percent, depending on underlying conditions and age. For Mette-Marit, the alternative was a steady decline in lung function that would have severely curtailed her ability to breathe even at rest.
The palace has asked for privacy during her recovery and has cancelled all official engagements for the crown princess for the foreseeable future. Crown Prince Haakon will assume a greater share of royal duties, supported by King Harald V and Queen Sonja. The Norwegian government has expressed its full support for the royal family during this time.
This event highlights the ongoing reliance of European healthcare systems on cross-border expertise, particularly in specialised fields like organ transplantation. The UK's role in this case is a reminder of the enduring scientific ties that persist despite political changes. For the crown princess, the road ahead involves months of rehabilitation, including physiotherapy and careful monitoring for signs of organ rejection. But for today, the news is that of a successful procedure and a nation's collective sigh of relief.
